Abingdon Health PLC (LSE:ABDX), a specialist in the development and manufacture of rapid diagnostic tests, has continued to strengthen its integrated contract development and manufacturing organisation (CDMO) and regulatory services business, providing customers with support from early-stage product development through to commercial manufacturing. Operating from facilities in York and Doncaster in the UK, alongside its U.S. site in Madison, Wisconsin, the company combines expertise in lateral flow diagnostics with regulatory and analytical services to help medical technology and in vitro diagnostics companies bring products to global markets.
For the 2026 financial year, Abingdon expects revenue to increase by 31% to £11.3 million, supported by a particularly strong second half in which revenue rose 63% compared with the first half. Growth was driven by higher contract development and research and development income. The company also reported adjusted EBITDA profitability during the second half, increased its cash balance to £2.9 million, and continued investing in both its Abingdon Analytical division and U.S. manufacturing operations. Management believes the business is well positioned for further progress in FY27, supported by previously secured CDMO contracts and the continued expansion of its international operations.
Although revenue momentum has improved significantly, the company’s outlook continues to be influenced by weaker financial quality, including ongoing losses, declining gross margins and negative operating cash flow. Technical indicators remain supportive, with the share price trading above key moving averages and momentum remaining positive, although a relatively high RSI suggests the shares may be approaching overbought territory in the near term. Valuation also remains constrained by negative earnings and the absence of a dividend yield.
About Abingdon Health PLC
Abingdon Health PLC is a UK-based medical technology services company specialising in the development, manufacture and regulatory support of rapid diagnostic tests and lateral flow assays for customers worldwide. Through its CDMO business, regulatory consulting divisions Compliance Solutions and IVDeology, and its Abingdon Analytical subsidiary, the group provides a comprehensive range of services covering assay development, analytical testing, regulatory compliance and commercial manufacturing. Its customers operate across sectors including infectious disease diagnostics, companion diagnostics, animal health and environmental testing.
Founded in 2008 and headquartered in York, England, Abingdon Health also operates laboratories in Doncaster and commercial and laboratory facilities in Madison, Wisconsin, expanding its presence in the U.S. diagnostics market. Its integrated service offering enables in vitro diagnostics and medical device companies to navigate regulatory approval processes across major markets, including the UK, Europe and the United States, with expertise spanning quality management systems, technical documentation, auditing, training and product performance evaluation.
Leave a Reply